Be sure to check our sister interview main ratings news website

Northland Capital partners view on Motif Bio PLC “Milestone moment”

Northland Capital partners view on Motif Bio PLC: The reprocessing of this acquired API will save Motif considerable time and money, representing an important milestone for the business. As such, we are confident that the company is on target to complete its two planned Phase III skin trials by the end of 2017.

 

Iclaprim Clinical Trial Supplies Manufactured
n  Motif Bio announced that clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured.

n  Following Quality Assurance release, these supplies will be shipped to clinical trial sites.

n  The group was able to utilise commercial-scale batches of the API (Active Pharmaceutical Ingredient) that it acquired earlier in the year as part of its merger with Nuprim Inc.

n  This API was reprocessed to generate new material and can now be used to manufacture further sterile ampoules for clinical trial supplies.
Year end Dec Revs ($m) Adj. EBITDA ($m) Adj. PBT ($m) Tax (%) Adj. EPS (c) PER (x) Div (c) Net cash ($m) Yield (%)
2012A – (0.7) (1.1) – (13.3) – – (6.6) –
2013A – (0.7) (1.1) – (13.2) – – (6.8) –
2014A – (1.1) (1.2) – (10.0) – – (6.8) –
2015E – (2.0) (2.9) – (4.7) – – 31.3 –

Source: Northland Capital Partners Limited.

 
 
Read in Full
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Motif Bio Plc

    More articles like this

    Motif Bio Plc

    Motif Bio plc Proposed Placing to raise approximately £19.4m

    2nd June 2017

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a conditional placing with new and

    Motif Bio Plc

    Motif Bio PLC Reports Year-End 2016 Financial Results

    2nd May 2017

    Motif Bio PLC (LON:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. Motif Bio made significant progress in 2016 towards our goal of

    Motif Bio Plc

    Motif Bio plc Update post NASDAQ IPO

    20th January 2017

    Motif Bio plc (LON:MTFB, NASDAQ:MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the funds from the IPO the company

    Motif Bio Plc

    Motif Bio plc appoint ex NASDAQ listed Tyme Technologies CFO

    18th January 2017

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional

    Motif Bio Plc

    Motif Bio PLC Update on US Public Offering

    31st October 2016

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, further to its announcement of 9 August 2016, said today that it is continuing to work towards pricing of its proposed public

    Motif Bio Plc

    Motif Bio plc 2 posters at ID Week in New Orleans

    15th September 2016

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.

    Motif Bio Plc

    Motif Bio plc progressing trials efficiently with latest update

    8th September 2016

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has given DirectorsTalk an update to REVIVE-1, one of Motif Bio’s two Phase 3 clinical trials currently enrolling patients with Acute

    © 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.